MSTR
Strategy Inc
There isn't enough reported data to score MSTR yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MSTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
MSTR's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MSTR PE Valuation
MSTR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MSTR Forward outlook
There aren't enough analyst estimates for MSTR to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MSTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$57.71 | -374% |
| Q2 2026 | -$94.04 | -960% |
| Q1 2026 | -$36.99 | -$14.75 |
| Q4 2025 | -$15.23 | -$9.17 |
| Q3 2025 | $21.07 | +$23.35 |
| Q2 2025 | $10.93 | +$12.50 |
| Q1 2025 | -$22.24 | -$21.39 |
| Q4 2024 | -$6.06 | -330% |
MSTR has swung to a loss: it lost $57.71 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MSTR on earnings quality, reporting a profit while its opponent remains loss making.
MSTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $125.4M | -2.5% |
| Q2 2026 | $122.4M | +6.9% |
| Q1 2026 | $124.3M | +12% |
| Q4 2025 | $123M | +1.9% |
| Q3 2025 | $128.7M | +11% |
| Q2 2025 | $114.5M | +2.7% |
| Q1 2025 | $111.1M | -3.6% |
| Q4 2024 | $120.7M | -3% |
MSTR's revenue has picked up after five years of holding roughly level: $125M last quarter, down 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16671% | +13648 points |
| Q2 2026 | -6808% | -19064 points |
| Q1 2026 | -11642% | -6310 points |
| Q4 2025 | -14185% | -13343 points |
| Q3 2025 | 3023% | +3396 points |
| Q2 2025 | 12256% | +12436 points |
| Q1 2025 | -5331% | -5155 points |
| Q4 2024 | -842% | -808 points |
MSTR has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over MSTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
MSTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4M | +$15.1M |
| Q2 2026 | -$5.9M | +$31.1M |
| Q1 2026 | $13M | +$18.2M |
| Q4 2025 | -$22.2M | -$4.6M |
| Q3 2025 | -$11.1M | +$30.3M |
| Q2 2025 | -$37M | -$13M |
| Q1 2025 | -$5.1M | -119% |
| Q4 2024 | -$17.6M | -2204% |
MSTR has burned cash in six of the last eight quarters: −$11M over the past year, against −$71M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over MSTR on cash generation, producing positive trailing cash flow while its opponent burns cash.
MSTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +75.5M shares |
| 1 year | +36% | +113M shares |
| 3 years | +201% | +286M shares |
| 5 years | +328% | +328M shares |
| Available history | +314% | +325M shares |
MSTR has 428M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $744,000 |
| Q3 2020 | $60.6M |
| Q2 2020 | $11.1M |
| Q1 2020 | $50.7M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MSTR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MSTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.2x | Healthy |
| Q3 2020 | -5.2x | Net Cash |
| Q2 2020 | -11.9x | Net Cash |
| Q1 2020 | -17.1x | Net Cash |
| Q4 2019 | -29.1x | Net Cash |
MSTR's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MSTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 42.1 | Neutral |
MSTR's weekly RSI is 42 (neutral) and its Stochastic is 42 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MSTR PE vs Technology Sector
| Metric | MSTR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
MSTR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MSTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.2 | 19% below |
| 20 week MA | $123.6 | 7.4% below |
| 50 week MA | $138.1 | 17% below |
| 100 week MA | $235.9 | 52% below |
| 200 week MA | $168.2 | 32% below |
MSTR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over MSTR on trend strength, trading above more of its moving averages.
MSTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.5 | $32.3 | +123% |
| 2021 | $32.3 | $59.7 | +85% |
| 2022 | $59.7 | $16.3 | -73% |
| 2023 | $16.3 | $63.2 | +288% |
| 2024 | $63.2 | $330.0 | +422% |
| 2025 | $330.0 | $158.8 | -52% |
| 2026 YTD | $158.8 | $114.4 | -28% |
MSTR's yearly returns have swung widely, from +422% in 2024 to −73% in 2022. It's down 28% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over MSTR on returns for 2026, with the stronger performance.